buyModerate

Cormorant Asset Management, LP bought $3.2M of DRUG

owner at BRIGHT MINDS BIOSCIENCES INC.. 422,591 shares at an average of $7.65, traded Oct 15, 2024, filed Oct 17, 2024.

Conviction score

Value

$3.2M

422,591 shares

Holdings after

875,000

+93% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
10% owner
+12
Trade size
$3.2M at market
+25
Relative to holdings
Holdings up 93%
+10
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0
Outside holder
A 10% owner who is not an officer or director
-5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +82.5%, 3m +68.7%, 6m +52.6%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

DRUGOct 9, 2026 · close 54.05

Since filing Oct 17, 2024: +149.1%SPY +36.8% · excess +112.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000929638-24-003542, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+238,097	$4.53	$1.1M	690,506	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+63,173	$5.92	$374k	753,679	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+33,343	$6.42	$214k	787,022	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+8,900	$7.31	$65k	795,922	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+2,600	$8.80	$23k	798,522	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+2,700	$9.26	$25k	801,222	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+19,169	$11.72	$225k	820,391	Oct 17, 2024
Oct 15, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+4,609	$12.35	$57k	825,000	Oct 17, 2024
Oct 16, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+39,743	$23.22	$923k	864,743	Oct 17, 2024
Oct 16, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+7,150	$24.03	$172k	871,893	Oct 17, 2024
Oct 16, 2024	POpen-market purchase Common Sharesindirect: See Footnote	+3,107	$25.22	$78k	875,000	Oct 17, 2024

Related signals

Other insiders at BRIGHT MINDS BIOSCIENCES INC. and this insider’s other filings.

Score	Company	Insider	Value	Holdings	Filed
43Moderate	DRUGbuy BRIGHT MINDS BIOSCIENCES INC.	Cormorant Asset Management, LP owner	$4.0M 184,331 shares	+21%	Nov 6, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.